Cetuximab and Panitumumab are FDA-approved mAbs against EGFR, and Erlotinib and Gefitinib are EGFR-TKIs first-line therapies for patients with non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.